Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRAF V600E-pulsed DC1 vaccine
- Development stage
- Preclinical
- Lead developer
- Elicio Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
The BRAF V600E-pulsed DC1 vaccine is an experimental autologous cancer immunotherapy designed to treat melanomas harboring the BRAF V600E mutation. The vaccine utilizes Type 1-polarized dendritic cells (DC1), which are specialized antigen-presenting cells optimized to induce potent Th1-type immunity and activate cytotoxic CD8+ T-lymphocytes. These DC1 cells are loaded (pulsed) with an affinity-modified peptide derived from the mutated BRAF V600E oncoprotein. Upon administration, the vaccine presents this specific mutant peptide to the patient's immune system, training CD8+ T-cells to recognize and selectively eliminate cancer cells expressing the BRAF V600E mutation. Preclinical studies in murine melanoma models have demonstrated that this approach can induce robust oncogene-specific immune responses, leading to delayed tumor growth and improved survival.
- Other names
- BRAF(V600E)-pulsed DC1 vaccineBRAF V600E-pulsed Type 1-polarized dendritic cell vaccine
Beyond the preview
Go deeper on BRAF V600E-pulsed DC1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRAF V600E-pulsed DC1 vaccine.